keyword
MENU ▼
Read by QxMD icon Read
search

Agomelatin

keyword
https://www.readbyqxmd.com/read/29773358/-antidepressive-agents-and-hyponatremia-a-literature-review-and-a-case-non-case-study-in-the-french-pharmacovigilance-database
#1
Michaël Rochoy, Christina Zakhem-Stachera, Johana Béné, Christophe Berkhout, Sophie Gautier
OBJECTIVE: Most antidepressants have been associated with a risk of hyponatremia in the literature. This effect is not always reported in monographs. The aim of our study was to clarify the difference of increased risk of hyponatremia among various antidepressants. METHODS: Retrospective study of such cases/non-cases from observations recorded in the French national pharmacovigilance between 01/01/2004 and 31/12/2013. We studied all antidepressants marketed in 2014 in France, with a positive control (haloperidol) and a negative one (amoxicillin)...
March 1, 2018: Thérapie
https://www.readbyqxmd.com/read/29765326/descriptions-of-adverse-drug-reactions-are-less-informative-in-forums-than-in-the-french-pharmacovigilance-database-but-provide-more-unexpected-reactions
#2
Pierre Karapetiantz, Florelle Bellet, Bissan Audeh, Jérémy Lardon, Damien Leprovost, Rim Aboukhamis, François Morlane-Hondère, Cyril Grouin, Anita Burgun, Sandrine Katsahian, Marie-Christine Jaulent, Marie-Noëlle Beyens, Agnès Lillo-Le Louët, Cédric Bousquet
Background: Social media have drawn attention for their potential use in Pharmacovigilance. Recent work showed that it is possible to extract information concerning adverse drug reactions (ADRs) from posts in social media. The main objective of the Vigi4MED project was to evaluate the relevance and quality of the information shared by patients on web forums about drug safety and its potential utility for pharmacovigilance. Methods: After selecting websites of interest, we manually evaluated the relevance of the content of posts for pharmacovigilance related to six drugs (agomelatine, baclofen, duloxetine, exenatide, strontium ranelate, and tetrazepam)...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29764215/myotonic-dystrophytype-1-report-of-non-24-h-sleep-wake-disorder-with-excessive-daytime-sleepiness
#3
Lucio Huebra Pimentel Filho, Ana Carolina Dias Gomes, Bruno Gonçalves, Sergio Tufik, Fernando Morgadinho Coelho
Myotonic dystrophy (MD) is a neuromuscular disease with myotonia, progressive weakness, and involvement of CNS, heart, and gastrointestinal system. Excessive daytime sleepiness (EDS) in myotonic dystrophy type 1 (MD1) is related to sleep breathing diseases, restless leg syndrome, periodic limb movements during sleep and narcoleptic-like phenotype. However, authors highlight a central dysfunction of sleep regulation. We describe a 26-year-old, female, MD1 patient with EDS. Sleep diary/actigraphy evidenced two different circadian periods with values of 1442 and 1522 min...
May 15, 2018: Chronobiology International
https://www.readbyqxmd.com/read/29734455/response-to-agomelatine-treatment-is-independent-of-smoking-status-and-dosage-results-from-the-agopsych-study
#4
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Sarah Eisenacher, Jascha Thiem, Andreas Meyer-Lindenberg, Mathias Zink
INTRODUCTION: Cigarette smoking influences response to antidepressant treatment. It accelerates the metabolism of several cytochrome P450 (CYP) subtypes, including CYP1A2, and therefore bears the risk of pharmacokinetic interactions with psychotropic drugs using that pathway. Agomelatine is a substrate of CYP1A2; the association between nicotine use and agomelatine dosage, however, has never been studied before. METHODS: Smoking habits were correlated with agomelatine doses and treatment outcomes in a sample of 27 patients with lifetime diagnoses within the schizophrenia spectrum who received agomelatine treatment in addition to their stable antipsychotic treatment regimen because of depressive symptoms...
May 7, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29729125/a-rapid-and-sensitive-lc-ms-ms-method-for-analysis-of-iguratimod-in-human-plasma-application-to-a-pharmacokinetic-study-in-chinese-healthy-volunteers
#5
Ying Xia, Shunbo Zhao, Meng Gong, Li Ding
A rapid, sensitive and reproducible LC-MS/MS method was developed and validated to determine iguratimod in human plasma. Sample preparation was achieved by protein precipitation with acetonitrile. Chromatographic separation was operated on an Ultimate® XB-C18 column (2.1 × 50 mm, 3.5 μm, Welch) with a flow rate of 0.400 mL/min, using a gradient elution with acetonitrile and water which contained 2 mM ammonium acetate and 0.1% formic acid as the mobile phase. The detection was performed on a Triple QuadTM 5500 mass spectrometer coupled with electrospray ionization interface under positive-ion multiple reaction monitoring mode with the transition ion pairs of m/z 375...
May 5, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29723928/effect-of-abcb1-c3435t-polymorphism-on-pharmacokinetics-of-antipsychotics-and-antidepressants
#6
Miriam Saiz-Rodríguez, Carmen Belmonte, Manuel Román, Dolores Ochoa, Carolina Jiang-Zheng, Dora Koller, Gina Mejía, Pablo Zubiaur, Aneta Wojnicz, Francisco Abad-Santos
P-glycoprotein, encoded by ABCB1, is an ATP-dependent drug efflux pump which exports substances outside the cell. Some studies described connections between C3435T polymorphism T allele and lower P-glycoprotein expression; therefore homozygous T/T could show higher plasma levels. Our aim was to evaluate the effect of C3435T on pharmacokinetics of 4 antipsychotics (olanzapine, quetiapine, risperidone and aripiprazole) and 4 antidepressants (trazodone, sertraline, agomelatine and citalopram). The study included 473 healthy volunteers receiving a single oral dose of one of these drugs, genotyped by real-time PCR...
May 3, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29718600/relative-efficacy-and-acceptability-of-antidepressant-drugs-in-adults-with-major-depressive-disorder-commentary-on-a-network-meta-analysis
#7
Chittaranjan Andrade
A large number of antidepressant drugs are available across the world. All have been compared against placebo, and many have been compared with some but not all other antidepressants. There is therefore little information about a hierarchy of the efficacy and acceptability of these drugs. About 9 years ago, a network meta-analysis attempted to rank the efficacy and acceptability of 12 newer antidepressant drugs in adults with major depressive disorder. Very recently, this network meta-analysis was updated to include 21 antidepressant drugs, most of which were introduced during the 1980s and afterward...
March 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29699692/melatonin-receptor-signaling-impact-of-receptor-oligomerization-on-receptor-function
#8
Atsuro Oishi, Erika Cecon, Ralf Jockers
The melatonin receptor subfamily is composed of three members, MT1 and MT2 , which are binding to melatonin, and GPR50, which shows high sequence homology to MT1 and MT2 but does not bind to melatonin or any other known ligand. An interesting feature of these receptors is their capacity to form homo- and heteromers between each other and also with other GPCRs. The following heteromers have been described: MT1 /MT2 , MT1 /GPR50, and heteromers composed of MT2 and the serotonin 5-HT2c receptor or the orphan GPR61, GPR62, and GPR135 receptors...
2018: International Review of Cell and Molecular Biology
https://www.readbyqxmd.com/read/29653194/chronic-agomelatine-treatment-prevents-comorbid-depression-in-the-post-status-epilepticus-model-of-acquired-epilepsy-through-suppression-of-inflammatory-signaling
#9
Jana Tchekalarova, Dimitrinka Atanasova, Lidia Kortenska, Milena Atanasova, Nikolai Lazarov
Inflammatory signal molecules are suggested to be involved in the mechanism underlying comorbid depression in epilepsy. In the present study, we tested the hypothesis that the novel antidepressant agomelatine, a potent melatonin MT1 and MT2 receptor agonist and serotonin 5HT2C receptor antagonist, can prevent depressive symptoms developed during the chronic epileptic phase by suppressing an inflammatory response. Chronic treatment with agomelatine (40 mg/kg, i.p.) was initiated an hour after the kainate acid (KA)-induced status epilepticus (SE) and maintained for a period of 10 weeks in Wistar rats...
July 2018: Neurobiology of Disease
https://www.readbyqxmd.com/read/29652308/-clinical-psychopathological-aspects-of-therapeutic-effects-of-agomelatine-valdoxan-and-its-place-in-perfection-of-methods-of-therapy-of-postschizophrenic-depressive-disorders
#10
G P Panteleyeva, L I Abramova, T E Novozhenova, N V Subbotskaya, D V Tikhonov, P E Yumatova, I Yu Nikiforova
AIM: To determine a therapeutic effect of agomelatine (valdoxan) on post-schizophrenic depression (PSD), taking into account its psychopathological structure. MATERIAL AND METHODS: A total of 33 patients of both sexes (average age was 32.1 yrs) with symptoms of post-schizophrenic depression (F20.4 according to ICD-10) were examined by using clinical and psychometric methods in the dynamics of shift-like schizophrenia. HAMD-17, PANSS and CGI-S scales were applied...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29620692/efficacy-and-safety-of-agomelatine-vs-paroxetine-hydrochloride-in-chinese-han-patients-with-major-depressive-disorder-a-multicentre-double-blind-noninferiority-randomized-controlled-trial
#11
Yi-Min Yu, Ke-Run Gao, Hao Yu, Yi-Feng Shen, Hua-Fang Li
PURPOSE: The purpose of this study is to investigate the efficacy, safety, and tolerability of agomelatine and paroxetine in Chinese Han patients with major depressive disorder (MDD). METHODS: A 8-week, double-blind, randomized, parallel study was conducted in 14 medical centers in mainland China from December 2011 to September 2012. A total of 264 subjects with a primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of MDD were randomly assigned to receive agomelatine 25-50 mg/d (n = 132) or paroxetine 20-40 mg/d (n = 132)...
April 3, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29593392/oral-bioavailability-enhancement-of-agomelatine-by-loading-into-nanostructured-lipid-carriers-peyer-s-patch-targeting-approach
#12
Jagruti B Prajapati, Sneha D Verma, Amit A Patel
Agomelatine (AGM) is a new antidepressant drug with a novel mechanism of action and fewer side effects compared with older antidepressants. AGM is a melatonin receptor (MT1 and MT2) agonist and 5-hydroxytryptamine receptor (5-HT2C ) antagonist. In the present study, the enhancement of the oral bioavailability of AGM was formulated and loaded into nanostructured lipid carriers (NLCs), using ultrasonication method. In vitro and ex vivo drug release was performed using a dialysis bag and rat duodenum, respectively...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29563776/inhibitory-effect-of-celecoxib-on-agomelatine-metabolism-in-vitro-and-in-vivo
#13
Jiayang He, Ping Fang, Xiang Zheng, Chenchen Wang, Tenghui Liu, Bowen Zhang, Jian Wen, Ren-Ai Xu
Aim: The aim of this study was to study the effect of celecoxib on agomelatine metabolism in vitro and in vivo. Methods: Ten healthy male Sprague-Dawley rats were randomly divided into 2 groups: Group A (control group) and Group B (30 mg/kg celecoxib). Then a single dose of 20 mg/kg agomelatine was administered orally 30 min after administration of celecoxib. In an in vitro study, celecoxib with a series of concentrations was added to an incubation mixture containing recombinant human CYP2C9, human or rat liver microsomes to determine the half-maximal inhibitory concentration on the metabolism of agomelatine...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29560946/-treatment-of-depression-with-cognitive-impairment
#14
V E Medvedev, A Yu Ter-Israelyan, V I Frolova, E A Korovyakova, E V Gushanskaya
AIM: To investigate the efficacy and tolerability of monotherapy with agomelatine (valdoxan) in depressive patients with marked cognitive impairment. MATERIAL AND METHODS: Thirty-five patients (women 77.1%) were recruited to participate in the study. Mean age of patients was 48.9±3.5 years. The following scales and cognitive tests were used: HAM-21, CGI, HADS, MMSE, the Stroop task, the Rey test, RAVLT. Effective therapeutic doses of valdoxan were 25mg per day in 77...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29554497/efficacy-and-tolerability-of-vortioxetine-versus-agomelatine-categorized-by-previous-treatment-in-patients-with-major-depressive-disorder-switched-after-an-inadequate-response
#15
George I Papakostas, Rebecca Z Nielsen, Marianne Dragheim, Brigitte Tonnoir
This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-blind, 12-week comparator study were randomized (1:1) to vortioxetine (10-20 mg/day) or agomelatine (25-50 mg/day). The pre-defined primary efficacy endpoint was change from baseline to week 8 in MADRS total score analyzed by MMRM. An ANCOVA-LOCF was conducted as a sensitivity analysis...
June 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29497298/agomelatine-versus-paroxetine-in-treating-depressive-and-anxiety-symptoms-in-patients-with-chronic-kidney-disease
#16
Jian-Wei Chen, Shu-Qin Xie
Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies focus on the interventions to manage or prevent these symptoms in CKD patients. Therefore, this study was conducted to compare the efficacy and acceptability of agomelatine versus paroxetine in treating depressive and anxiety symptoms in CKD patients. Methods: CKD stage 2-4 patients with depressive and anxiety symptoms were included...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29487083/drugs-for-insomnia-beyond-benzodiazepines-pharmacology-clinical-applications-and-discovery
#17
REVIEW
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontinuation, car accidents/falls, abuse, and dependence liability. Consequently, the clinical use of off-label drugs and novel drugs that do not target the GABAergic system is increasing. The purpose of this review is to analyze the neurobiological and clinical evidence of pharmacological treatments of insomnia, excluding the BZDs and Z-drugs...
April 2018: Pharmacological Reviews
https://www.readbyqxmd.com/read/29477251/comparative-efficacy-and-acceptability-of-21-antidepressant-drugs-for-the-acute-treatment-of-adults-with-major-depressive-disorder-a-systematic-review-and-network-meta-analysis
#18
Andrea Cipriani, Toshi A Furukawa, Georgia Salanti, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins, Matthias Egger, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aran Tajika, John P A Ioannidis, John R Geddes
BACKGROUND: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder...
April 7, 2018: Lancet
https://www.readbyqxmd.com/read/29458117/agomelatine-s-effect-on-circadian-locomotor-rhythm-alteration-and-depressive-like-behavior-in-6-ohda-lesioned-rats
#19
Leonardo C Souza, Bruno J Martynhak, Taysa B Bassani, Joelle de M Turnes, Meira M Machado, Eric Moura, Roberto Andreatini, Maria A B F Vital
Parkinson's disease (PD) patients often suffer from circadian locomotor rhythms impairment and depression, important non-motor symptoms. It is known that toxin-based animal models of PD can reproduce these features. In a 6-hydroxydopamine (6-OHDA) intranigral model, we first investigated the possible disturbances on circadian rhythms of locomotor activity. The rats were divided into 6-OHDA and Sham groups. After a partial dopaminergic lesion, the 6-OHDA group showed slight alterations in different circadian locomotor rhythms parameters...
May 1, 2018: Physiology & Behavior
https://www.readbyqxmd.com/read/29440213/does-industry-sponsored-education-foster-overdiagnosis-and-overtreatment-of-depression-osteoporosis-and-over-active-bladder-syndrome-an-australian-cohort-study
#20
Barbara Mintzes, Swestika Swandari, Alice Fabbri, Quinn Grundy, Ray Moynihan, Lisa Bero
OBJECTIVES: To investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment. DESIGN AND SETTING: This retrospective cohort study examines publicly reported industry-sponsored events in Australia from October 2011 to September 2015 for three conditions potentially subject to overdiagnosis and overtreatment: depression, osteoporosis and overactive bladder. We used a database of transparency reports to identify events with a focus on depression, osteoporosis and overactive bladder and compared these with other sponsored events...
February 13, 2018: BMJ Open
keyword
keyword
118315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"